Vaccines - Switzerland | Statista Market Forecast

The Vaccines market in Switzerland is expected to witness a significant growth in revenue, projected to reach US$391.40m CHF by 2024.
This growth is anticipated to continue at an annual growth rate of 7.00% from 2024 to 2029, resulting in a market volume of US$548.90m CHF by 2029.
When comparing the global market, it is noteworthy that United States is expected to generate the highest revenue in the Vaccines market, with an estimated value of US$29.12bn in 2024.
Switzerland's commitment to precision and quality is evident in its vaccine market, where cutting-edge research and rigorous testing ensure the highest standards of safety and efficacy.

Definition:
This market covers vaccines against infectious diseases. They help to prevent diseases, usually through active immunization. Vaccines against infectious diseases transmitted by viruses (e.g., hepatitis A and B or COVID-19) and bacteria (e.g., typhoid fever or meningococcus) are included.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Pfizer, GlaxoSmithKline, Merck & Co, Sanofi, Moderna, AstraZeneca

Vaccines against infectious diseases
Prophylactic and therapeutic vaccines
Flu vaccines
COVID-19 vaccines

Sera and gammaglobulins
Antivirals
Antibiotics

The Swiss healthcare system is known for its high quality and accessibility, with a strong emphasis on preventive care. This has led to a growing demand for vaccines in Switzerland, as individuals seek to protect themselves and their families from preventable diseases.

Customer preferences: Swiss consumers are increasingly concerned about the safety and efficacy of vaccines, and are willing to pay a premium for high-quality products. They also place a strong emphasis on convenience and accessibility, with many opting for vaccines that can be administered at home or in a pharmacy.

Trends in the market: The vaccines market in Switzerland is growing steadily, driven by an aging population and increasing awareness of the importance of preventive care. There has been a particular focus on vaccines for infectious diseases such as influenza, HPV, and meningococcal disease, as well as travel vaccines for those heading to high-risk areas.

Local special circumstances: Switzerland has a highly decentralized healthcare system, with cantons responsible for the provision and financing of healthcare services. This has led to variations in vaccine coverage and access across the country, with some cantons offering more comprehensive vaccination programs than others.

Underlying macroeconomic factors: Switzerland has a strong economy and high levels of healthcare spending, which has helped to support the growth of the vaccines market. However, rising healthcare costs and an aging population are putting pressure on the system, which may lead to changes in the way vaccines are financed and delivered in the future. Additionally, Switzerland's position as a global hub for pharmaceuticals and life sciences has attracted significant investment in research and development, which may lead to new and innovative vaccines in the coming years.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

As of March 2023, more than 13 billion COVID-19 vaccine doses had been administered worldwide. Wide-spread vaccine availability, increasing herd immunity, and lower case numbers led to renewed hope and a feeling of normality in 2023. However, especially during the winter seasons and with the potential emergence of new variants of the virus (like Omicron in 2021-2022), tracking of coronavirus cases repeatedly becomes a focus for the public. Thus, there is a level of uncertainty about what developments the winter season 2023/2024 might bring.